AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35292074 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion on the navel
Number of subjects: 210
Study 35292074 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 210
Study 34556318 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 0
Study 34556318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33452406 — intervention group
Group type: EXPERIMENTAL
Intervention: 45°-tilt view
Number of subjects: 49
Study 33452406 — intervention group
Group type: EXPERIMENTAL
Intervention: 45°-rotation plus 45°-tilt view
Number of subjects: 49
Study 33452406 — intervention group
Group type: COMPARATOR
Intervention: Neutral view
Number of subjects: 49
Study 33452406 — intervention group
Group type: EXPERIMENTAL
Intervention: 45°-rotation view
Number of subjects: 49
Study 34689182 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCCC group
Number of subjects: 56
Study 34689182 — intervention group
Group type: COMPARATOR
Intervention: NPCCC group
Number of subjects: 56
Study 34580500 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit gaming
Number of subjects: 90
Study 34580500 — intervention group
Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 90
Study 32222589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol and aspirin
Number of subjects: 1194
Study 32222589 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 1194
Study 32222589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol administration
Number of subjects: 1194
Study 32222589 — intervention group
Group type: EXPERIMENTAL
Intervention: New-AF group
Number of subjects: 1194
Study 32222589 — intervention group
Group type: COMPARATOR
Intervention: Non-AF group
Number of subjects: 1194
Study 34304054 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 and irinotecan plus bevacizumab (experimental group)
Number of subjects: 487
Study 34304054 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6/CapeOX plus bevacizumab (control group)
Number of subjects: 487
Study 32674792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg daily prior to completion of gestational week 10, maintained through pregnancy
Number of subjects: 54
Study 32674792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) alone (after excluding 9 mothers on confounding medications)
Number of subjects: 54
Study 32674792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 54
Study 35605625 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous booster vaccination with low dose aerosolised Ad5-nCoV (1·0×10^11 viral particles per mL; 0·1 mL)
Number of subjects: 420
Study 35605625 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous booster vaccination with high dose aerosolised Ad5-nCoV (1·0×10^11 viral particles per mL; 0·2 mL)
Number of subjects: 420
Study 35605625 — intervention group
Group type: COMPARATOR
Intervention: Homologous intramuscular vaccination with CoronaVac (0·5 mL)
Number of subjects: 420
Study 35605625 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous booster vaccination with low dose aerosolised Ad5-nCoV
Number of subjects: 420
Study 35605625 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous booster vaccination with high dose aerosolised Ad5-nCoV
Number of subjects: 420
Study 35605625 — intervention group
Group type: COMPARATOR
Intervention: Homologous intramuscular vaccination with CoronaVac
Number of subjects: 420
Study 33087480 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (DexM) 2 µg/kg
Number of subjects: 90
Study 33087480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 35109880 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) - 3 bouts of 9-min intervals at 90% of HRmax, interspersed by 1 min rest, 5 days a week for 4 weeks
Number of subjects: 40
Study 35109880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 33040610 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxin-A (treatment)
Number of subjects: 93
Study 33040610 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium-chloride solution (placebo)
Number of subjects: 93
Study 32079331 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss intervention
Number of subjects: 28
Study 35562778 — intervention group
Group type: EXPERIMENTAL
Intervention: REALIST ORBCEL‐C (400 × 106 cells or maximal tolerated dose in phase 1)
Number of subjects: 120
Study 35562778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35698954 — intervention group
Group type: EXPERIMENTAL
Intervention: 6h cold-ischemia time (CIT)
Number of subjects: 8
Study 35698954 — intervention group
Group type: EXPERIMENTAL
Intervention: 12h cold-ischemia time (CIT)
Number of subjects: 8
Study 35698954 — intervention group
Group type: COMPARATOR
Intervention: Both 6h and 12h CIT
Number of subjects: 8
Study 32224795 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactor study designs
Number of subjects: 0
Study 32224795 — intervention group
Group type: COMPARATOR
Intervention: Single-treatment trial
Number of subjects: 0
Study 33508953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ULDCT) (80 kVp and 5 mAs)
Number of subjects: 336
Study 33508953 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose CT (SDCT) (120 kVp and 100 mAs)
Number of subjects: 336
Study 34553396 — intervention group
Group type: EXPERIMENTAL
Intervention: Low expressed emotion (EE) group
Number of subjects: 121
Study 34553396 — intervention group
Group type: COMPARATOR
Intervention: High expressed emotion (EE) group
Number of subjects: 121
Study 32784263 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVOT with MI communication strategy
Number of subjects: 24
Study 36141875 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) stretching, 10 stretches total: isometric contraction (3-5 s) followed by stretching (25 s)
Number of subjects: 18
Study 36141875 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS), ankle joint held in maximum dorsiflexion for 30 s, n = 8
Number of subjects: 18
Study 36141875 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (PNF and SS)
Number of subjects: 18
Study 33404325 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control (CLC)
Number of subjects: 101
Study 33404325 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP)
Number of subjects: 101
Study 32349156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing narratives with specific words (e.g., 'urination', 'food supply', 'bowel mobility', 'pain')
Number of subjects: 33
Study 32349156 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning techniques for predicting LOS
Number of subjects: 33
Study 32349156 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical tests on nursing narratives
Number of subjects: 33
Study 35858264 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT LOUD
Number of subjects: 34
Study 35858264 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeechVive
Number of subjects: 34
Study 35858264 — intervention group
Group type: COMPARATOR
Intervention: nontreatment clinical control
Number of subjects: 34
Study 33914564 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection exposure
Number of subjects: 80
Study 33914564 — intervention group
Group type: COMPARATOR
Intervention: Neutral social cues
Number of subjects: 80
Study 33914564 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety (SA)
Number of subjects: 80
Study 33440262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump It Up! Personalized T1D Self‐Management Behaviors Feedback Report
Number of subjects: 0
Study 33440262 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump It Up! Problem‐Solving Skills intervention
Number of subjects: 0
Study 33440262 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33440262 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 0
Study 33440262 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome
Number of subjects: 0
Study 35366823 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) interventions
Number of subjects: 38
Study 33713680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 712
Study 33713680 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 712
Study 33713680 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 712
Study 35078830 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided algorithm used in conjunction with best practice
Number of subjects: 1942
Study 35078830 — intervention group
Group type: COMPARATOR
Intervention: Best practice alone
Number of subjects: 1942
Study 34544468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose Painting (DP) procedure with doses of 80, 85, and 91 Gy delivered to PTV1, PTV2, and PTV3 respectively.
Number of subjects: 20
Study 34544468 — intervention group
Group type: COMPARATOR
Intervention: Conventional IMRT
Number of subjects: 20
Study 34544468 — intervention group
Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiation Therapy (3DCRT)
Number of subjects: 20
Study 34544468 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up after 4 months
Number of subjects: 20
Study 33573608 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient energy management education (IEME) + high-intensity interval training (HIIT)
Number of subjects: 106
Study 33573608 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR) + moderate continuous training (MCT)
Number of subjects: 106
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased communication and sharing of resources between academic centers and community hospitals
Number of subjects: 18
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hospital engagement
Number of subjects: 18
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of the project in the community hospitals
Number of subjects: 18
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruiting patients
Number of subjects: 18
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hospitals' willingness to participate in RCTs
Number of subjects: 18
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of capacity for research in community hospitals
Number of subjects: 18
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial coordinating sites' efforts
Number of subjects: 18
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisibility of community hospitals to research investigators
Number of subjects: 18
Study 34008258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of research infrastructure in community hospitals
Number of subjects: 18
Study 33551116 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D instructional video
Number of subjects: 108
Study 33551116 — intervention group
Group type: COMPARATOR
Intervention: 2D instructional video
Number of subjects: 108
Study 33471654 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU intramuscular D2
Number of subjects: 40
Study 33471654 — intervention group
Group type: EXPERIMENTAL
Intervention: 400,000 IU intramuscular D2
Number of subjects: 40
Study 33471654 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 IU intramuscular D2
Number of subjects: 40
Study 33471654 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 35134995 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS 20 mg/kg
Number of subjects: 45
Study 35134995 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121 10 mg/kg
Number of subjects: 45
Study 35134995 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121 20 mg/kg
Number of subjects: 45
Study 35134995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antibodies
Number of subjects: 45
Study 35134995 — intervention group
Group type: COMPARATOR
Intervention: VRC07-523LS and PGT121
Number of subjects: 45
Study 35474643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-based coaching (12 weekly face-to-face sessions)
Number of subjects: 240
Study 35474643 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coaching)
Number of subjects: 240
Study 35508351 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen replacement using fibrinogen concentrate (FC)
Number of subjects: 68
Study 35508351 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate
Number of subjects: 68
Study 33908180 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning Algorithm (MLA)
Number of subjects: 553
Study 33908180 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression Model (LRM)
Number of subjects: 553
Study 33908180 — intervention group
Group type: COMPARATOR
Intervention: AST-to-Platelet ratio
Number of subjects: 553
Study 33908180 — intervention group
Group type: COMPARATOR
Intervention: FIB-4 score
Number of subjects: 553
Study 33908180 — intervention group
Group type: COMPARATOR
Intervention: NAFLD Fibrosis Score
Number of subjects: 553
Study 33150799 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 0
Study 33150799 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab
Number of subjects: 0
Study 33998672 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 10‐2474 (0.25–100 mg single dose)
Number of subjects: 116
Study 33998672 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 10‐2474 (2.5–50 mg repeated oral doses for 10 days)
Number of subjects: 116
Study 33998672 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 10‐2474 (50 mg repeated administration)
Number of subjects: 116
Study 33998672 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA 10‐2474
Number of subjects: 116
Study 33740232 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy surgery (resective surgeries such as lesionectomy, lobectomy, multilobar resections; disconnective surgeries such as corpus callosotomy)
Number of subjects: 0
Study 33740232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-surgical screening workup including high-resolution epilepsy protocol brain MRI and high-quality in-patient video EEG evaluation
Number of subjects: 0
Study 33740232 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced investigations (PET, SPECT, MEG)
Number of subjects: 0
Study 33740232 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI
Number of subjects: 0
Study 33740232 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive long-term EEG monitoring (using stereotactically implanted intracranial depth electrodes or subdural grids)
Number of subjects: 0
Study 33740232 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation (DBS, VNS, RNS)
Number of subjects: 0
Study 32069361 — intervention group
Group type: EXPERIMENTAL
Intervention: 810-nm diode laser
Number of subjects: 20
Study 35873352 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma (aPRP) combined with rabeprazole
Number of subjects: 27
Study 35873352 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole only (Control)
Number of subjects: 27
Study 32377957 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg)
Number of subjects: 76
Study 35700617 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping in addition to standard treatment (oral analgesics: acetaminophen q6h 1000 mg and NSAID, and sling if shoulder injury)
Number of subjects: 83
Study 35700617 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (oral analgesics: acetaminophen q6h 1000 mg and NSAID, and sling if shoulder injury)
Number of subjects: 83
Study 32918917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear regression analysis for predicting tissue/blood distribution coefficients
Number of subjects: 282
Study 32918917 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual tissue/blood distribution coefficient models
Number of subjects: 282
Study 36493331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel film (MF)
Number of subjects: 376
Study 36493331 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 376
Study 34620193 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized music intervention
Number of subjects: 54
Study 32966293 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP plus 3TC (lamivudine)
Number of subjects: 20
Study 35490691 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-centred care
Number of subjects: 1748
Study 35490691 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1748
Study 34933684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (0-14 days regimen)
Number of subjects: 809
Study 34933684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (0-21 days regimen)
Number of subjects: 809
Study 34933684 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (0-28 days regimen)
Number of subjects: 809
Study 36044097 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy (warm white-light exposure at 10,000 lx for 30 min per day for 12 weeks)
Number of subjects: 13
Study 36044097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 13
Study 34580169 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) guided treatment strategy
Number of subjects: 102
Study 34580169 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102
Study 33429088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 120
Study 33429088 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 120
Study 32123573 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injector lidocaine delivery
Number of subjects: 0
Study 32123573 — intervention group
Group type: COMPARATOR
Intervention: Traditional needle lidocaine delivery
Number of subjects: 0
Study 33594596 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen endotracheal tubes (DL-ETT)
Number of subjects: 39
Study 33594596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial blockers (BB)
Number of subjects: 39
Study 32367144 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 10 Hz
Number of subjects: 30
Study 32367144 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no tACS)
Number of subjects: 30
Study 32367144 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 70 Hz
Number of subjects: 30
Study 35022623 — intervention group
Group type: COMPARATOR
Intervention: Portable immunosensor for detecting Mycobacterium tuberculosis (MTB) in sputum; optimal source voltage (0.3 V) and gate voltage (0.1 V) used.
Number of subjects: 0
Study 35022623 — intervention group
Group type: COMPARATOR
Intervention: Portable immunosensor for detecting Mycobacterium tuberculosis (MTB) in sputum; anti-interference tests with common proteins in simulated saliva.
Number of subjects: 0
Study 35022623 — intervention group
Group type: COMPARATOR
Intervention: Portable immunosensor for detecting Mycobacterium tuberculosis (MTB) in sputum; optimized dilution gradient of actual TB sputum samples.
Number of subjects: 0
Study 32409986 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Course (intervention group)
Number of subjects: 60
Study 32409986 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 32016788 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT‐AFL T&E with 2-week adjustments
Number of subjects: 246
Study 32016788 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT‐AFL T&E with 4-week adjustments
Number of subjects: 246
Study 36192724 — intervention group
Group type: EXPERIMENTAL
Intervention: selfBACK app
Number of subjects: 26
Study 33605206 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney discard risk index (derived from 21 factors)
Number of subjects: 102246
Study 33605206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom 10th percentile of kidney discard risk index
Number of subjects: 102246
Study 33605206 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 10th percentile of kidney discard risk index
Number of subjects: 102246
Study 33605206 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for discard
Number of subjects: 102246
Study 35969882 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) alone
Number of subjects: 10739
Study 35969882 — intervention group
Group type: COMPARATOR
Intervention: Estrogen-alone therapy (from meta-analysis)
Number of subjects: 10739
Study 34105307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 34105307 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35435791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 51
Study 35435791 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy (MBT)
Number of subjects: 51
Study 35435791 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (Control)
Number of subjects: 51
Study 33465316 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing hypertonic saline
Number of subjects: 0
Study 33465316 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing dornase alfa
Number of subjects: 0
Study 33465316 — intervention group
Group type: COMPARATOR
Intervention: Continuing hypertonic saline
Number of subjects: 0
Study 33465316 — intervention group
Group type: COMPARATOR
Intervention: Continuing dornase alfa
Number of subjects: 0
Study 32086889 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down pharmacotherapy (n=67)
Number of subjects: 135
Study 32086889 — intervention group
Group type: COMPARATOR
Intervention: Maintaining therapy (n=68)
Number of subjects: 135
Study 34744069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling Suspension Therapy (SST)
Number of subjects: 40